Self-pay options for Mounjaro without insurance

If you’re considering medications like Wegovy, Ozempic, or Mounjaro for weight loss or diabetes management, you’re probably asking the same question thousands of Americans ask every day: Will my insurance cover this?

The short answer: It depends—on your insurance type, your diagnosis, and sometimes even which state you live in.

GLP-1 medications have transformed treatment for Type 2 diabetes and obesity, but their high cost (often over $1,000 per month without insurance) means coverage can make or break your ability to access them. In this guide, we’ll walk you through exactly what insurance plans typically cover, what hoops you might need to jump through, and what to do if your claim gets denied.

Understanding the Basics: What Are These Medications?

Before diving into coverage, let’s clarify what we’re talking about:

• Wegovy (semaglutide): FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition like high blood pressure or Type 2 diabetes.

• Ozempic (semaglutide): FDA-approved for Type 2 diabetes management. While chemically identical to Wegovy, Ozempic is not approved for weight loss—though many doctors prescribe it off-label for that purpose.

• Mounjaro (tirzepatide): FDA-approved for Type 2 diabetes. Its weight-loss counterpart, Zepbound, is approved for obesity treatment.

All three belong to a class called GLP-1 receptor agonists (or GIP/GLP-1 agonists for Mounjaro), which work by mimicking hormones that regulate blood sugar and appetite.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: The Coverage Maze

What Most Plans Cover (and Don’t Cover)

For diabetes: Most commercial insurance plans cover Ozempic and Mounjaro when prescribed for Type 2 diabetes. These are considered essential medications for managing a chronic condition, so insurers generally include them on formularies—though often on higher cost-sharing tiers (Tier 3 or 4).

For weight loss: This is where it gets tricky. Many employer-sponsored health plans exclude coverage for anti-obesity medications entirely, treating them as optional benefits rather than medical necessities. Even when plans do cover Wegovy or other weight-loss drugs, they typically impose strict requirements.

According to recent data, fewer than half of large employers offer coverage for GLP-1 weight-loss medications, citing the drugs’ high costs and concerns about long-term budget impact.

Prior Authorization: The First Hurdle

If your plan covers weight-loss GLP-1s at all, you’ll almost certainly face prior authorization (PA). Here’s what insurers typically require:

For Wegovy or weight-loss use:

• BMI threshold: Usually BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (like hypertension, sleep apnea, or prediabetes)
• Documented lifestyle attempts: Proof of at least 6 months of supervised diet and exercise programs that didn’t achieve adequate weight loss
• Age requirements: Generally 18 years or older (some plans have upper age limits)
• No contraindications: Verification that you don’t have conditions that make the medication unsafe

For Ozempic or Mounjaro (diabetes use):

• Confirmed Type 2 diabetes diagnosis
• Evidence that first-line treatments (like metformin) haven’t adequately controlled blood sugar, or documentation of why those medications aren’t appropriate
• Recent A1c levels showing need for additional therapy

Many insurers also want to see you’re using the medication appropriately—some require regular check-ins with your doctor and proof of ongoing lifestyle modifications.

Step Therapy Requirements

Step therapy means you must ‘step through’ cheaper treatment options before insurance will pay for more expensive medications. For weight loss, this might mean:

1. Trying older, less expensive medications (like phentermine or orlistat) first
2. Attempting a structured weight-loss program
3. Using an older GLP-1 like Saxenda (liraglutide) before accessing Wegovy

For diabetes, you might need to try metformin or a sulfonylurea before your insurer approves a GLP-1 drug.

The frustrating part? Step therapy requirements vary wildly by plan. Some insurers waive these steps if you have severe obesity (BMI ≥35) or significant cardiovascular risk factors.

Typical Tier Placement and Costs

When covered, these medications usually fall into:

• Tier 3 (Non-preferred brand): 25-40% coinsurance or $50-150 copay
• Tier 4 (Specialty): 25-50% coinsurance, often with high monthly caps

With typical coinsurance, you might pay $250-500 per month even with insurance coverage. Some plans cap specialty drug costs at $200-300 monthly, which can help make these medications more affordable.

Medicare Coverage: Limited but Evolving

Part D Standard Coverage

Here’s the hard truth: Traditional Medicare Part D does not cover medications prescribed solely for weight loss. This is federal law—Medicare is prohibited from covering ‘drugs used for weight loss’ under the Social Security Act.

However, there’s an important exception: Medicare will cover these drugs when prescribed for their FDA-approved non-weight-loss indications:

• Ozempic and Mounjaro: Covered for Type 2 diabetes management under Part D
• Wegovy: As of March 2024, Medicare covers Wegovy specifically for cardiovascular risk reduction in patients with established heart disease and obesity—not for weight loss as a primary indication

This means if you have Type 2 diabetes, Medicare will likely cover Ozempic or Mounjaro (subject to your plan’s formulary and any prior authorization requirements). But if you want Wegovy purely for weight management without cardiovascular disease, you’re out of luck with traditional Medicare.

Medicare Advantage Plans

Some Medicare Advantage plans have begun offering limited coverage for weight-loss medications as supplemental benefits in 2025. These plans can provide benefits beyond traditional Medicare, and a small but growing number include GLP-1s for obesity treatment.

If weight-loss medication coverage matters to you, compare Medicare Advantage plans carefully during open enrollment—but expect significant restrictions and high cost-sharing even when covered.

Medicaid Coverage: A State-by-State Patchwork

Medicaid coverage for GLP-1 weight-loss medications varies dramatically by state. As of late 2025, only about 13 states provide coverage—and that number is shrinking as states grapple with budget pressures.

States Currently Covering (with Major Changes)

New York: Covers Wegovy with prior authorization requiring BMI ≥30 (or ≥27 with comorbidities), documented lifestyle modification, and quantity limits. PA typically takes 5-10 business days.

Pennsylvania: Currently covers Wegovy with strict criteria, including BMI thresholds and required attempts at lifestyle intervention. Important update: Pennsylvania Medicaid will discontinue coverage for weight-loss GLP-1s effective January 2026 due to budget constraints.

California: Covered Wegovy through 2025 with prior authorization (BMI ≥30 or ≥27 with comorbidity, 6-month supervised diet required). Critical change: California’s Medi-Cal is eliminating adult coverage for weight-loss GLP-1s effective January 1, 2026. Pediatric coverage may continue under EPSDT (Early and Periodic Screening, Diagnostic and Treatment) provisions for children under 21.

States NOT Covering

Texas: Explicitly excludes all obesity medications for adults over 21. Texas Medicaid designates weight-loss drugs as non-covered since March 2023. Children may request exceptions via EPSDT, but adult coverage is prohibited by state policy.

Florida: Does not cover weight-loss medications, invoking the optional federal exclusion. Only diabetes-indicated GLP-1s (Ozempic, Mounjaro) are covered when prescribed for Type 2 diabetes.

Illinois: No coverage for anti-obesity drugs in Medicaid as of 2025, despite expanding coverage for state employees in 2023.

Why the Coverage Cuts?

States are pulling back on GLP-1 obesity coverage primarily because of cost. With list prices around $1,350 per month for Wegovy, states face potential budget increases of hundreds of millions of dollars as demand grows. California cited projected costs of $3 billion annually as the reason for ending coverage.

This creates a cruel irony: Medicaid populations have higher obesity rates than commercially insured groups, yet they’re losing access to these breakthrough treatments due to budget constraints.

Common Reasons for Denial (and How to Fight Them)

Even when your plan theoretically covers GLP-1 medications, denials happen frequently. Here are the top reasons—and what you can do:

1. Not Meeting BMI Requirements

The issue: Your documented BMI falls below the required threshold (usually BMI <30 without comorbidities, or <27 with comorbidities).

The solution: Ensure your healthcare provider documents your weight and height accurately in your medical record. If you’re close to the threshold, discuss whether any measurement errors occurred. Some plans accept measurements from home scales with physician attestation.

2. Insufficient Documentation of Lifestyle Attempts

The issue: No record of the required 6+ months of supervised diet and exercise programs.

The solution: Work with your doctor to document your weight-loss attempts retroactively if possible. This might include:

• Notes from nutritionist visits
• Records from weight-loss programs (like Weight Watchers, Jenny Craig)
• Gym membership records showing regular attendance
• Food journals reviewed by your provider

Many patients have done the work but never had it formally documented—so make sure everything is in your medical chart with dates and outcomes noted.

3. Off-Label Use Denial

The issue: Your insurer rejected coverage for Ozempic because you’re using it for weight loss (off-label) rather than diabetes.

The solution: If you have Type 2 diabetes, make sure that’s the primary diagnosis on the prescription. If you don’t have diabetes and want semaglutide for weight loss, your doctor should prescribe Wegovy instead—it’s the same medication but FDA-approved for obesity, which improves your coverage odds.

4. Missing Step Therapy

The issue: Your plan requires trying cheaper alternatives first, but there’s no record of those attempts.

The solution: Ask your doctor whether you have documented contraindications or failures with first-line treatments. If you’ve tried and failed on older weight-loss medications, or if there’s a medical reason you can’t take them (like uncontrolled hypertension with phentermine), get that in writing. Some insurers will waive step therapy if you have severe obesity (BMI ≥35) or significant cardiovascular risk.

5. Plan Exclusion

The issue: Your policy explicitly excludes all weight-loss medications, regardless of medical necessity.

The solution: This is the hardest denial to overcome. You can appeal by arguing alternative covered uses (treating prediabetes, PCOS, or metabolic syndrome), but success rates are low. Consider asking your employer’s HR department if they’ll add obesity drug coverage during the next plan year. Otherwise, you may need to pay out-of-pocket or explore manufacturer assistance programs.

The Appeals Process: Your Rights and Strategy

If you receive a denial, don’t give up. Insurance companies expect most people won’t appeal—but appeals often succeed when you have proper documentation.

Step 1: Internal Appeal (Required First)

Contact your insurance company within the timeframe specified in your denial letter (usually 180 days). Submit:

• A letter from your doctor explaining medical necessity
• Complete medical records showing you meet all criteria
• Scientific literature supporting the treatment (your doctor can help with this)
• Documentation of lifestyle attempts and their outcomes

Timeline: Insurers must respond to standard appeals within 30 days, or 72 hours for urgent appeals (when delay could seriously jeopardize your health).

Step 2: External Review

If your internal appeal fails, you have the right to external review by an independent third party. This is often more successful because the reviewer isn’t financially motivated to deny your claim.

Step 3: Consider Legal or Advocacy Help

If you’re still denied and believe the decision is wrong, consider:

• Contacting your state insurance commissioner
• Working with a patient advocacy organization
• Consulting with a healthcare attorney (especially if you’re facing discrimination or your denial violates state or federal law)

Reality check: Appeals work best when you actually meet the criteria but paperwork was incomplete. If your plan explicitly excludes weight-loss drugs or you genuinely don’t meet medical criteria, appeals rarely succeed. But when documentation gaps are the issue, persistence pays off—studies suggest 30-40% of initially denied prior authorizations for appropriate GLP-1 use are approved on appeal.

Telehealth and Insurance: Good News for Access

Here’s one area where things work in your favor: most insurance plans now cover telehealth visits for weight management at the same rate as in-person care.

Since the COVID-19 pandemic, telehealth parity laws have expanded dramatically. Over 40 states now require private insurers to cover telehealth services equivalently to in-person visits, and Medicare has permanently expanded telehealth coverage.

What this means for you:

• Virtual consultations with weight-loss specialists typically count toward prior authorization requirements
• Nutritional counseling via telehealth is covered under the ACA’s preventive services mandate
• Follow-up visits to monitor medication response can be done remotely
• Many insurance plans now contract directly with telehealth platforms or allow your PCP to bill for virtual visits

One caveat: Make sure any telehealth provider you use is in-network with your insurance. Platforms like Klarity Health offer transparent pricing and accept both insurance and self-pay, with accessible providers available for virtual consultations—but always verify coverage before your appointment.

The convenience of telehealth is especially valuable for weight management, which requires ongoing monitoring. You can check in with your provider monthly without taking time off work or arranging transportation, making it easier to meet the documented follow-up requirements many insurers demand.

When Insurance Won’t Cover: Self-Pay Options That Won’t Break the Bank

If insurance denies your claim or you don’t have coverage, don’t assume these medications are out of reach. Recent price reductions and savings programs have made self-pay much more feasible.

Manufacturer Savings Programs

For Wegovy:

• NovoCare Savings Card: If you have commercial insurance (even if it doesn’t cover the drug), you may qualify for as little as $0 copay, with Novo Nordisk covering up to $225 per month
• Self-pay program: Novo offers Wegovy at $349 per month through their direct access program (down from the $1,350 list price)—a 74% discount

For Ozempic:

• Diabetes Savings Card: For patients with Type 2 diabetes and commercial insurance, copays as low as $25 per month
• Patient Assistance Program: Free medication for uninsured patients meeting income criteria (typically <400% of federal poverty level)

For Mounjaro:

• Lilly Savings Card: $25 monthly for up to 12 months for commercially insured patients with Type 2 diabetes (covers up to $500 off)
• Patient Assistance: Lilly provides Mounjaro at no cost to eligible uninsured or underinsured patients

GoodRx Game-Changer

In November 2025, GoodRx partnered with Novo Nordisk to offer breakthrough pricing:

• $199 per month for the first two months of Wegovy or Ozempic
• $349 per month ongoing for most doses
• Available at nearly all major pharmacy chains nationwide

This represents a 60-70% discount off list prices and makes these medications accessible to many more Americans paying out-of-pocket.

Eli Lilly’s Zepbound Vials

For Zepbound (tirzepatide for weight loss), Lilly introduced single-dose vials at:

• $299/month for 2.5 mg dose
• $399/month for 5 mg dose
• $449/month for higher doses (down from $549)

These vial formulations cost significantly less than pre-filled pens and can save hundreds per month.

Patient Assistance Programs

Both Novo Nordisk and Eli Lilly offer patient assistance programs providing free medication for up to 12 months for those who qualify. Eligibility typically requires:

• Being uninsured or underinsured (medication not covered)
• U.S. citizenship or legal residency
• Income below certain thresholds (usually 400% of federal poverty level, or about $60,000 for an individual in 2025)

Applications can be completed online with your doctor’s help, and approval often comes within 1-2 weeks.

Alternative Medications

If GLP-1s remain unaffordable, consider discussing these options with your doctor:

• Older weight-loss medications: Phentermine, orlistat, or combination drugs like Contrave typically cost $30-100 per month and are more likely to be covered by insurance
• Metformin: Often prescribed off-label for weight loss in people with prediabetes or PCOS; very inexpensive (often <$10/month)
• Lifestyle programs: Some evidence-based programs (like the CDC’s National Diabetes Prevention Program) are fully covered by most insurance plans and have proven effectiveness

A word of caution: Avoid compounded semaglutide or tirzepatide from online wellness clinics or telehealth companies offering ultra-low prices. These formulations aren’t FDA-approved, may not contain the claimed amounts of active ingredient, and carry safety risks. While they’re cheaper (sometimes $200-300/month), the lack of regulation makes them a risky choice.

What to Do Right Now: Your Action Plan

If You’re Just Starting to Explore Coverage:

1. Check your insurance formulary: Log into your insurance portal or call member services to see if Wegovy, Ozempic, or Mounjaro are covered under your specific plan.

2. Request a benefits check: Ask your doctor’s office to submit a benefits verification before you start treatment—this will reveal any prior authorization requirements and your expected out-of-pocket costs.

3. Document everything: Start keeping records of your weight-loss attempts, including dates, programs tried, and outcomes. Take photos of food journals, gym receipts, or program completion certificates.

4. Schedule a consultation: Consider a virtual visit with a qualified provider who specializes in weight management. Klarity Health offers convenient telehealth appointments with board-certified providers who understand the insurance landscape and can help navigate prior authorization requirements. With transparent pricing and availability in multiple states, you can get expert guidance on the most cost-effective path to treatment—whether through insurance or self-pay options.

If You’ve Been Denied:

1. Request the written denial: Get the specific reason in writing so you know exactly what’s missing.

2. Work with your provider: Schedule a follow-up with your doctor to gather any missing documentation or explore alternative diagnoses that might improve coverage.

3. File a formal appeal: Don’t wait—submit your appeal within the required timeframe with comprehensive supporting documentation.

4. Explore self-pay options: While appealing, investigate manufacturer programs and GoodRx pricing so you have a backup plan.

If You’re Paying Out of Pocket:

1. Apply for manufacturer savings: Visit NovoCare.com (for Wegovy/Ozempic) or LillyDirect.com (for Mounjaro/Zepbound) to see if you qualify for patient assistance or savings cards.

2. Compare pharmacy prices: Check GoodRx.com for the lowest prices at pharmacies near you—sometimes prices vary by $100+ between chains.

3. Consider the vial option: If using Zepbound, ask about the single-dose vials which cost significantly less than pens.

4. Ask about samples: Some providers have manufacturer samples for the first month, allowing you to try the medication while sorting out longer-term coverage.

The Bottom Line

Insurance coverage for GLP-1 medications like Wegovy, Ozempic, and Mounjaro remains frustratingly inconsistent in 2025. Whether you get coverage often depends more on your insurance type, employer decisions, and state policies than on medical need.

Key takeaways:

• Commercial insurance usually covers diabetes uses (Ozempic, Mounjaro) but often excludes or restricts weight-loss medications (Wegovy)
• Medicare doesn’t cover drugs purely for weight loss, though it covers diabetes indications
• Medicaid coverage varies wildly by state and is shrinking due to budget pressures
• Prior authorization is nearly universal for these medications, requiring extensive documentation
• Telehealth visits are now widely covered and can help you meet insurance requirements more conveniently
• Self-pay options have improved dramatically in late 2025, with prices dropping from $1,000+ to $200-400/month through manufacturer programs

If your insurance denies coverage, don’t assume you’re out of options. Between appeals, manufacturer assistance programs, and new discount pricing, many patients can access these life-changing medications at manageable costs.

Ready to explore your treatment options? Whether you need help navigating insurance coverage or want to discuss self-pay alternatives, starting with a knowledgeable provider makes all the difference. Klarity Health’s experienced clinicians offer virtual consultations with transparent pricing—$0 if you have insurance that covers telehealth visits, or affordable cash-pay rates. With providers available across the U.S., you can get expert guidance on the most cost-effective path to the medication that’s right for you.

📅 Research Currency Statement

Verified as of December 17, 2025

This guide reflects the most current coverage policies, pricing, and availability as of December 2025. Insurance formularies and state Medicaid policies were verified through official sources, and pricing reflects manufacturer programs announced in late 2025. Given the rapidly evolving landscape of GLP-1 coverage, always verify your specific insurance benefits and state policies before starting treatment.

References

1. Aetna Clinical Policy Bulletin – Weight Loss GLP-1 Agonists. Aetna.com. May 2024. https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html

2. California DHCS Medi-Cal Announcement. CMADocs.org. December 2025. https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal

3. Cohen J. ‘Coverage of Weight Loss Drugs by Medicaid Plans Continues to Lag.’ Forbes. August 7, 2025. https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/

4. Kaiser Family Foundation. ‘Medicaid Coverage of and Spending on GLP-1s.’ KFF Issue Brief. November 4, 2024. https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/

5. GoodRx Press Release. ‘GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription.’ BusinessWire. November 17, 2025. https://www.businesswire.com/news/home/20251117268209/en/GoodRx-Launches-New-%2439-Per-Month-Weight-Loss-Telemedicine-Subscription-Unveils-Industry-Leading-Introductory-Cash-Price-of-%24199-Per-Month-for-Ozempic-and-Wegovy

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499